News
ATRA
8.10
-0.98%
-0.08
Atara Biotherapeutics files $200M mixed securities shelf
TipRanks · 14h ago
Atara Biotherapeutics Files Base Prospectus Related To The Offer, Issuance And Sale Of Up To $200M In Securities
Benzinga · 14h ago
Atara Biotherapeutics reports Q3 EPS (15c), consensus (22c)
TipRanks · 15h ago
Atara Biotherapeutics says cash sufficient to fund operations into mid-2027
TipRanks · 15h ago
Atara Biotherapeutics GAAP EPS of -$0.15 beats by $0.07, revenue of $1.22M beats by $0.69M
Seeking Alpha · 15h ago
*Atara Biotherapeutics 3Q Loss $2.23M >ATRA
Dow Jones · 15h ago
Press Release: Atara Biotherapeutics Announces -2-
Dow Jones · 15h ago
*Atara Biotherapeutics 3Q Loss/Shr 15c >ATRA
Dow Jones · 15h ago
Press Release: Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
Dow Jones · 15h ago
Atara Biotherapeutics: Q3 Earnings Snapshot
Barchart · 20h ago
Weekly Report: what happened at ATRA last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at ATRA last week (1026-1030)?
Weekly Report · 11/02 10:07
Weekly Report: what happened at ATRA last week (1019-1023)?
Weekly Report · 10/26 10:07
Atara Biotherapeutics Defendants Move to Dismiss Amended Securities Class Action Over Tab-cel FDA Rejection
TipRanks · 10/23 09:25
Weekly Report: what happened at ATRA last week (1012-1016)?
Weekly Report · 10/19 10:07
Canaccord Genuity Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)
TipRanks · 10/15 11:37
Atara partner receives acceptance by FDA of BLA resubmission for tabelecleucel
TipRanks · 10/14 12:20
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Benzinga · 10/14 12:08
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
Barchart · 10/14 07:05
Weekly Report: what happened at ATRA last week (1005-1009)?
Weekly Report · 10/12 10:11
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.